Quantity of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some people who will be labeled as possessing mild or average ailment could have a serious bleeding https://hemgenix60482.full-design.com/5-easy-facts-about-hemgenix-described-78141745